Our vision
To build a biopharmaceutical company that can compete globally, from research and development through manufacturing and commercialization.
Founded in Shanghai in 2012, Junshi Biosciences discovers, develops and commercializes medicines. Our teams work across oncology, autoimmune and metabolic disorders, and infectious diseases.

To build a biopharmaceutical company that can compete globally, from research and development through manufacturing and commercialization.
To provide patients with innovative medicines they can trust and afford.
We value quality, practical work grounded in evidence, integrity and compliance, and the pursuit of excellence.
Meet the people who guide Junshi’s research, clinical development, manufacturing and commercial operations.

Executive Director and Vice Chairman
View profile
Executive Director, General Manager and Chief Executive Officer
View profile
Executive Director and Co-Chief Executive Officer
View profile
Executive Director and Deputy General Manager
View profile
Executive Director, Senior Vice President of Industry Affairs and Chief Quality Officer
View profile
Executive Director and Senior Vice President of Government Affairs
View profile
Chief Medical Officer
View profile
Chief Commercial Officer
View profileJunshi Biosciences was founded in Shanghai.
Toripalimab received its first marketing approval in China, for previously treated advanced melanoma.
The US FDA approved toripalimab-tpzi for two adult nasopharyngeal carcinoma treatment settings.
Read the FDA decisionThe European Commission authorized Loqtorzi for specified indications in nasopharyngeal and esophageal squamous cell carcinoma.
Read the European public assessment reportToripalimab has received marketing approval in more than 50 countries and regions. Explore the markets identified in our disclosures and our research and manufacturing sites in eastern China.
Highlighted markets have granted marketing approval for toripalimab.

31.23° N · 121.47° E
The Shanghai team screens drug candidates and develops processes and analytical methods.

31.30° N · 120.59° E
The Suzhou team validates drug candidates, develops processes and supports pilot production.

30.90° N · 121.85° E
Phase I has 42,000 L of fermentation capacity for clinical and commercial manufacturing.

31.16° N · 120.65° E
The site has 4,500 L of fermentation capacity and supplies toripalimab to overseas markets.